Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8933 results

  1. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

    Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.

  2. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA923

  3. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  4. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

  5. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  6. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

  7. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

  8. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  9. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

  10. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

  11. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

  12. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic prioritisation

  13. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

  14. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation